Cardiovascular risk in post-myocardial infarction patients: Nationwide real world data demonstrate the importance of a long-term perspective

European Heart Journal

Volumn 36, Issue 19, 2015, Pages 1163-1170a

  Jernberg, Tomas ^a   Hasvold, Pål ^b   Henriksson, Martin ^b   Hjelm, Hans ^c   Thuresson, Marcus ^d   Janzon, Magnus ^e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c Nyköping Hospital   (Sweden)

^d STATISTICON AB   (Sweden)

^e LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Mortality; Myocardial infarction; Nationwide register data; Prognosis; Risk factors

Indexed keywords

ADULT; AGED; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; FEMALE; GROUPS BY AGE; HEART FAILURE; HEART INDEX; HEART INFARCTION; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVASCULARIZATION; REVIEW; SWEDEN; VERY ELDERLY; CARDIOVASCULAR DISEASE; DISEASE COURSE; EPIDEMIOLOGY; HOSPITALIZATION; KAPLAN MEIER METHOD; MORTALITY; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; FEMALE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; STROKE; SWEDEN;

EID: 84928969008     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu505     Document Type: Review

References (31)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2011;3:e442.
2. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J 2013;34:3028-3034.
3. Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. Circulation 2011;124:314-323.
4. Nichols M, Townsend N, Scarborough P, Rayner M. Trends in age-specific coronary heart disease mortality in the European Union over three decades: 1980-2009. Eur Heart J 2013;34:3017-3027.
5. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxarinthe secondary preventionofatherothrombotic events.NEngl J Med 2012;366:1404-1413.
6. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of athero-thrombotic events. N Engl J Med 2006;354:1706-1717.
7. Bonaca MP, Bhatt DL, Braunwald E, Cohen M, Steg PG, Storey RF, Held P, Jensen EC, Sabatine MS. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014;167:437-444.
8. Ludvigsson JF, Andersson A, Ekbom A, Feychting M, Kim J-L, Reuterwall C, Heurgren M, Olausson PO. External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450.
9. Linnersjö A, Hammar N, Gustavsson A, Reuterwall C. Recent time trends in acute myocardial infarction in Stockholm, Sweden. Int J Cardiol. 2000;76:17-21.
10. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundström A, Westerholm B, Rosén M. ThenewSwedishPre-scribed Drug Register-opportunities for pharmacoepidemiological research and experience from thefirst six months. Pharmacoepidemiol Drug Saf 2007;16:726-735.
11. Chung SC, Gedeborg R, Nicholas O, James S, Jeppsson A, Wolfe C, Heuschmann P, Wallentin L, Deanfield J, Timmis A, Jernberg T, Hemingway H. Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK. Lancet 2014; 383:1305-1312.
12. Glickman SW, Ou FS, DeLong ER, Roe MT, Lytle BL, Mulgund J, Rumsfeld JS, Gibler WB, Ohman EM, Schulman KA, Peterson ED. Pay for performance, quality of care, and outcomes in acute myocardial infarction. JAMA 2007;297:2373-2380.
13. 2012 Annual Report (English edition). http://www.ucr.uu.se/swedeheart/index. php/arsrapporter (7 March 2014).
14. Erne P, Gutzwiller F, Urban P, Maggiorini M, Keller PF, Radovanovic D. Characteristics and outcome inacute coronary syndrome patients with and without established modifiable cardiovascular risk factors: insights from the nationwide AMIS Plus Registry 1997-2010. Cardiology 2012;121:228-236.
15. Bajaj RR, Goodman SG, Yan RT, Bagnall AJ, Gyenes G, Welsh RC, Eagle KA, Brieger D, Ramanathan K, Grondin FR, Yan AT; Canadian GRACE and CANRACE Investigators. Treatment and outcomes of patients with suspected acute coronary syndromes in relation to initial diagnostic impressions (insights from the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE]). Am J Cardiol 2013;111:202-207.
16. Tousek P, Tousek F, Horak D, Cervinka P, Rokyta R, Pesl L, Jarkovsky J, Widimsky P, CZECH-2 Investigators. The incidence and outcomes of acute coronary syndromes in a central European country: results of the CZECH-2 registry. Int J Cardiol 2014; 173:204-208.
17. Jørgensen CH, Gislason GH, Ahlehoff O, Andersson C, Torp-Pedersen C, Hansen PR. Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus. BMC Cardiovasc Disord 2014;14:4.
18. Wallentin L, Becker RC, Budaj A, Cannon C, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1108-1111.
19. Varenhorst C, Jensevik K, Jernberg T, Sundstrom A, Hasvold P, Held C, Lagerqvist B, James S. Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndromes. Eur Heart J 2014;35:969-978.
20. Hvelplund A, Galatius S, Madsen M, Sørensen R, Madsen JK, Iversen AZ, Tilsted HH, Helqvist S, Mortensen PE, Nielsen PH, Prescott E, Abildstrøm SZ. Significance of the invasive strategy after acute myocardial infarction on prognosis and secondary preventive medication: a nationwide study of 6364 women and 11, 915 men. J Invasive Cardiol 2012;24:19-24.
21. Wijeysundera HC, Bennell MC, Qiu F, Ko DT, Tu JV, Wijeysundera DN, Austin PC. Comparative-effectiveness of revascularization versus routine medical therapy for stable ischemic heart disease: a population-based study. J Gen Intern Med 2014;29: 1031-1039.
22. Sørensen R, Gislason GH, Fosbøl EL, Rasmussen S, Køber L, Madsen JK, Torp-Pedersen C, Abildstrom SZ. Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Br J Clin Pharmacol 2008; 66:875-884.
23. Gislason GH, Rasmussen JN, Abildstrøm SZ, Gadsbøll N, Buch P, Friberg J, Rasmussen S, Køber L, Stender S, Madsen M, Torp-Pedersen C. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006;27:1153-1158.
24. Steg PG, Greenlaw N, Tardif JC, Tendera M, Ford I, Kääb S, Abergel H, Fox KM, Ferrari R; CLARIFY Registry Investigators. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J 2012;33:2831-2840.
25. Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med 2005; 143:659-672.
26. ESC. 2014. European Society of Cardiology EACPR website. http://www.escardio .org/communities/EACPR/about/EACPR-main-sections/Pages/EACPR-Cardiac-Rehabilitation.aspx. (6 June 2014).
27. AHA. 2014. American Heart Association cardiac rehabilitation website. http://www.heart.org/HEARTORG/Conditions/More/CardiacRehab/What-is-Cardiac-Rehabilitation-UCM-307049-Article.jsp. (6 June 2014).
28. Kotseva K, Wood D, De Backer G, De Bacquer D; EUROASPIRE III Study Group. Use and effects of cardiac rehabilitation in patients with coronary heart disease: results from the EUROASPIRE III survey. Eur J Prev Cardiol 2013;20:817-826.
29. Löfdahl CG, Tilling B, Ekström T, Jörgensen L, Johansson G, Larsson K. COPD health care in Sweden-a study in primary and secondary care. Respir Med 2010;104: 404-411.
30. Quan H, Li B, Saunders D, Parsons GA, Nilsson CI, Alibhai A, Ghali WA, for the IMECCHI Investigators. Assessing validity of ICD-9CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health Serv Res 2008;43:1424-1441.
31. ElBardissi AW, Aranki SF, Sheng S, O'Brien SM, Greenberg CC, Gammie JS. Trends in isolated coronary artery bypass grafting: An analysis of the Society of Thoracic Surgeons adult cardiac surgery database. J Thorac Cardiovasc Surg 2012;143:273-281.